









Markets
/
Stocks
/
nasdaq-inm
/

InMed Pharmaceuticals Inc

INM

1.730USD

-0.120-6.49%

Close 11/04, 16:00（ET）Quotes delayed by 15 min

3.46MMarket Cap

LossP/E TTM



InMed Pharmaceuticals Inc

1.730

-0.120-6.49%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of InMed Pharmaceuticals Inc

Currency: USD Updated: 2025-11-04

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Despite a very weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

InMed Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

234 / 407

Overall Ranking

464 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

InMed Pharmaceuticals Inc Highlights

StrengthsRisks

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 19.52% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 4.94M.

Fairly Valued

The company’s latest PE is -0.21, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 124.98K shares, increasing 23.56% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Financial Health

Currency: USD Updated: 2025-11-04

The company's current financial score is 6.66, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 1.30M, representing a year-over-year increase of 1.69%, while its net profit experienced a year-over-year increase of 7.71%.

Score

Industry at a Glance

Previous score

6.66

Change



Financials

8.63

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.47

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.28

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.79

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.13

Key Metrics

Free cash flow

No Data

InMed Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-11-04

The company’s current valuation score is 7.08, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.21, which is -10284.44% below the recent high of 21.07 and -416.24% above the recent low of -1.07.

Score

Industry at a Glance

Previous score

7.08

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 234/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-04

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-04

The company’s current price momentum score is 3.72, which is lower than the Biotechnology & Medical Research industry's average of 6.41. Sideways: Currently, the stock price is trading between the resistance level at 2.26 and the support level at 1.43, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.63

Change

0.09

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.065

Sell

RSI(14)

28.451

Sell

STOCH(KDJ)(9,3,3)

13.798

Oversold

ATR(14)

0.109

Low Volatility

CCI(14)

-154.069

Sell

Williams %R

89.907

Oversold

TRIX(12,20)

-0.655

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.838

Sell

MA10

1.939

Sell

MA20

2.067

Sell

MA50

2.157

Sell

MA100

2.394

Sell

MA200

2.643

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-04

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.15. The latest institutional shareholding proportion is 5.24%, representing a quarter-over-quarter decrease of 17.38%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 1.00% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Yorkville Advisors Global, LP.

80.37K

Sabby Management, LLC

36.13K

+135.22%

UBS Financial Services, Inc.

7.76K

+27.12%

Adams (Eric Ashley)

2.20K

-72.17%

Hull (Andrew Harold)

1.91K

-18.19%

Tower Research Capital LLC

400.00

SBI Securities Co., Ltd.

300.00

Banque Cantonale Vaudoise

6.00

Hsu (Eric Chih-Hsien)

2.00

-99.90%

Bessemer Trust Company, N.A. (US)

1.00

Risk Assessment

Currency: USD Updated: 2025-11-04

The company’s current risk assessment score is 3.34, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.29. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.